US-based Acura Pharmaceuticals has signed a license agreement to provide its Aversion Technology to KemPharm to use with its existing and in-development immediate release (IR) opioid product candidates.

Aversion Technology is composed of commonly used active and inactive pharmaceutical ingredients providing abuse deterrent features (ADF) and benefits for pharmaceutical drug products that are orally administered.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Under the agreement, Acura will receive $3.5 million at execution, while KemPharm will get development and commercialisation rights for up to three IR product candidates that contain two of KemPharm's opioid prodrugs.

KemPharm president and CEO Travis Mickle said: "Acura's Aversion Technology, an FDA-approved aversive ADF approach without a food effect, and KP201/IR, our priority lead product candidate, together offer significant potential benefits.

"We believe KemPharm shares our objective of aggressively developing and bringing to the healthcare community new abuse deterrent IR opioid analgesics to treat pain."

"We believe today's agreement will help us bridge the regulatory approval process between current abuse deterrence products and the ability of our new molecular entity prodrugs to demonstrate their ADF properties."

See Also:

Additional payments are made if KemPharm exercises its option to use Acura's technology with more than the three products.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Acura president Bob Jones said: "We are excited to partner with KemPharm who, like us, is committed to address the problem of prescription opioid abuse.

"We believe KemPharm shares our objective of aggressively developing and bringing to the healthcare community new abuse deterrent IR opioid analgesics to treat pain."